NTIDC research is proud to be the only site in Dallas that has been dosing with long-acting, injectable HIV-treatment since 2014.
Category: NTIDC News
Gilead’s new capsid inhibitor GS-6207 has started its phase 1b trial with the potential for 3 month dosing. The capsid inhibitor is currently being dosed by a subcutaneous injection but Gilead is attempting to develop a oral formulation of the antiretroviral.
At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a second case of an HIV positive adult cleared of the HIV virus after he received a bone marrow transplant from an HIV resistant donor was presented.
The DISCOVER trial was presented at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. The trial’s Phase 3, 96-week results for an updated formulation of PrEP compared to the current formulation was equally effective.